Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.

Abstract

The advent of Trikafta (Kaftrio in Europe) (a triple-combination therapy based on two correctors-elexacaftor/tezacaftor-and the potentiator ivacaftor) has represented a revolution for the treatment of patients with cystic fibrosis (CF) carrying the most common misfolding mutation, F508del-CFTR. This therapy has proved to be of great efficacy in people homozygous for F508del-CFTR and is also useful in individuals with a single F508del allele. Nevertheless, the efficacy of this therapy needs to be improved, especially in light of the extent of its use in patients with rare class II CFTR mutations. Using CFBE41o- cells expressing F508del-CFTR, we provide mechanistic evidence that targeting the E1 ubiquitin-activating enzyme (UBA1) by TAK-243, a small molecule in clinical trials for other diseases, boosts the rescue of F508del-CFTR induced by CFTR correctors. Moreover, TAK-243 significantly increases the F508del-CFTR short-circuit current induced by elexacaftor/tezacaftor/ivacaftor in differentiated human primary airway epithelial cells, a gold standard for the pre-clinical evaluation of patients' responsiveness to pharmacological treatments. This new combinatory approach also leads to an improvement in CFTR conductance on cells expressing other rare CF-causing mutations, including N1303K, for which Trikafta is not approved. These findings show that Trikafta therapy can be improved by the addition of a drug targeting the misfolding detection machinery at the beginning of the ubiquitination cascade and may pave the way for an extension of Trikafta to low/non-responding rare misfolded CFTR mutants.

• Authors: Christian Borgo, Claudio D'Amore, Valeria Capurro, Valeria Tomati, Elvira Sondo, Federico Cresta, Carlo Castellani, Nicoletta Pedemonte, Mauro Salvi
• Journal: Cellular and molecular life sciences : CMLS (Cell Mol Life Sci) Vol. 79 Issue 4 Pg. 192 (Mar 16 2022) ISSN: 1420-9071 [Electronic] Switzerland
• PMID: 35292885 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Aminophenols
• Benzodioxoles
• CFTR protein, human
• Enzyme Inhibitors
• Indoles
• Pyrazoles
• Pyridines
• Pyrimidines
• Pyrrolidines
• Quinolones
• Sulfides
• Sulfonamides
• UBA1 protein, human
• tezacaftor
• Cystic Fibrosis Transmembrane Conductance Regulator
• ivacaftor
• Ubiquitin-Activating Enzymes
• elexacaftor
• TAK-243

Topics

• Aminophenols (administration & dosage)
• Benzodioxoles (administration & dosage)
• Cells, Cultured
• Cystic Fibrosis (drug therapy, genetics, metabolism)
• Cystic Fibrosis Transmembrane Conductance Regulator (chemistry, genetics, metabolism)
• Drug Synergism
• Drug Therapy, Combination
• Enzyme Inhibitors (administration & dosage)
• Humans
• Indoles (administration & dosage)
• Mutation
• Protein Folding (drug effects)
• Pyrazoles (administration & dosage)
• Pyridines (administration & dosage)
• Pyrimidines (administration & dosage)
• Pyrrolidines (administration & dosage)
• Quinolones (administration & dosage)
• Sequence Deletion
• Sulfides (administration & dosage)
• Sulfonamides (administration & dosage)
• Ubiquitin-Activating Enzymes (antagonists & inhibitors)